506 related articles for article (PubMed ID: 32613971)
1. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
Qi X; Ke B; Feng Q; Yang D; Lian Q; Li Z; Lu L; Ke C; Liu Z; Liao G
Chem Commun (Camb); 2020 Aug; 56(61):8683-8686. PubMed ID: 32613971
[TBL] [Abstract][Full Text] [Related]
2. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
3. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
[TBL] [Abstract][Full Text] [Related]
4. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
[TBL] [Abstract][Full Text] [Related]
5. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.
Konwarh R
Front Immunol; 2020; 11():1531. PubMed ID: 32655584
[No Abstract] [Full Text] [Related]
6. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.
Li T; Zheng Q; Yu H; Wu D; Xue W; Xiong H; Huang X; Nie M; Yue M; Rong R; Zhang S; Zhang Y; Wu Y; Wang S; Zha Z; Chen T; Deng T; Wang Y; Zhang T; Chen Y; Yuan Q; Zhao Q; Zhang J; Gu Y; Li S; Xia N
Emerg Microbes Infect; 2020 Dec; 9(1):2076-2090. PubMed ID: 32897177
[TBL] [Abstract][Full Text] [Related]
8. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
[TBL] [Abstract][Full Text] [Related]
9. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 immunogenicity at the crossroads.
Karamloo F; König R
Allergy; 2020 Jul; 75(7):1822-1824. PubMed ID: 32401346
[No Abstract] [Full Text] [Related]
11. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
Chen WH; Tao X; Agrawal AS; Algaissi A; Peng BH; Pollet J; Strych U; Bottazzi ME; Hotez PJ; Lustigman S; Du L; Jiang S; Tseng CK
Vaccine; 2020 Nov; 38(47):7533-7541. PubMed ID: 33039209
[TBL] [Abstract][Full Text] [Related]
12. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.
Custódio TF; Das H; Sheward DJ; Hanke L; Pazicky S; Pieprzyk J; Sorgenfrei M; Schroer MA; Gruzinov AY; Jeffries CM; Graewert MA; Svergun DI; Dobrev N; Remans K; Seeger MA; McInerney GM; Murrell B; Hällberg BM; Löw C
Nat Commun; 2020 Nov; 11(1):5588. PubMed ID: 33149112
[TBL] [Abstract][Full Text] [Related]
13. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
Papageorgiou AC; Mohsin I
Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
[TBL] [Abstract][Full Text] [Related]
14. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.
Yi C; Yi Y; Li J
Virol Sin; 2020 Jun; 35(3):259-262. PubMed ID: 32524253
[No Abstract] [Full Text] [Related]
15. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
Dai L; Zheng T; Xu K; Han Y; Xu L; Huang E; An Y; Cheng Y; Li S; Liu M; Yang M; Li Y; Cheng H; Yuan Y; Zhang W; Ke C; Wong G; Qi J; Qin C; Yan J; Gao GF
Cell; 2020 Aug; 182(3):722-733.e11. PubMed ID: 32645327
[TBL] [Abstract][Full Text] [Related]
16. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.
Samrat SK; Tharappel AM; Li Z; Li H
Virus Res; 2020 Oct; 288():198141. PubMed ID: 32846196
[TBL] [Abstract][Full Text] [Related]
17. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
[TBL] [Abstract][Full Text] [Related]
18. Coronavirus vaccines get a biotech boost.
Dance A
Nature; 2020 Jul; 583(7817):647-649. PubMed ID: 32694847
[No Abstract] [Full Text] [Related]
19. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
Yu J; Tostanoski LH; Peter L; Mercado NB; McMahan K; Mahrokhian SH; Nkolola JP; Liu J; Li Z; Chandrashekar A; Martinez DR; Loos C; Atyeo C; Fischinger S; Burke JS; Slein MD; Chen Y; Zuiani A; Lelis FJN; Travers M; Habibi S; Pessaint L; Van Ry A; Blade K; Brown R; Cook A; Finneyfrock B; Dodson A; Teow E; Velasco J; Zahn R; Wegmann F; Bondzie EA; Dagotto G; Gebre MS; He X; Jacob-Dolan C; Kirilova M; Kordana N; Lin Z; Maxfield LF; Nampanya F; Nityanandam R; Ventura JD; Wan H; Cai Y; Chen B; Schmidt AG; Wesemann DR; Baric RS; Alter G; Andersen H; Lewis MG; Barouch DH
Science; 2020 Aug; 369(6505):806-811. PubMed ID: 32434945
[TBL] [Abstract][Full Text] [Related]
20. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2.
Tai W; Zhang X; Drelich A; Shi J; Hsu JC; Luchsinger L; Hillyer CD; Tseng CK; Jiang S; Du L
Cell Res; 2020 Oct; 30(10):932-935. PubMed ID: 32759966
[No Abstract] [Full Text] [Related]
[Next] [New Search]